11/20/2009 - Pfizer (NYSE:PFE) announced that the FDA approved Geodon Capsule for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data that demonstrated the drug is effective and generally well-tolerated for long-term symptom control in patients that have bipolar disorder. Clinical professor of psychiatry and pharmacology at the University of Texas Health Science Center Charles Bowden said, "The FDA approval of Geodon provides an additional treatment option for patients with bipolar disorder, who require maintenance therapy to keep the symptoms of the disease under control."

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html